KSILINK
- Company typePrivate
- Founded2014
- HeadquartersStrasbourg, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
KSILINK firmographics
Firmographics- Name
- KSILINK
- Legal name
- Ksilink
- Website
- https://ksilink.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
KSILINK industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
Keywords
Where KSILINK is headquartered
LocationHeadquarters
- HQ city
- Strasbourg
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
KSILINK business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Drug Discovery Partnerships: Ksilink generates revenue through research collaborations and service contracts with pharmaceutical companies, biotech firms, and academic institutions. They offer assay development, screening services, and co-development programs.
- Spin-off Companies: Ksilink creates spin-off companies from successful programs, such as Myrtil Biotechnologies for dilated cardiomyopathies, generating value through equity or licensing arrangements.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
KSILINK product offering
Product offeringCore offering
KSILINK designs and applies patient-derived and genome-edited cellular disease models for large-scale phenotypic drug discovery. It offers assay development, target identification, high-content phenotypic screening (using siRNA, CRISPR, and small molecule libraries), and AI-powered image and data analysis services to pharmaceutical, biotech, and academic partners. Its proprietary engine combines AI-boosted cellular profiling with patient-derived cellular systems to identify druggable targets and progress compounds toward clinical validation.
Product overview
KSILINK operates as a patient-based drug discovery platform offering a suite of services centered around its proprietary AI-boosted cellular profiling technologies. The core offering includes patient-based cellular disease models and assay development services for large-scale phenotypic screening, complemented by AI-powered image and data analysis services. The company provides end-to-end capabilities spanning assay development, target identification, screening solutions, and data science. In 2022, KSILINK established Myrtil Biotechnologies as a spin-off with myriamed GmbH to commercialize AI-powered dilated cardiomyopathy screening programs.
Differentiator
Problem solved
Functional benefit
Products and services
- Patient-Based Drug Discovery Services Comprehensive drug discovery services using patient-derived cellular disease models and complex cellular systems for large-scale phenotypic screening, supporting partners, customers, and in-house programs.
- Assay Development Services Development of primary and secondary phenotypic assays using complex human disease models, with focus on robustness and high-throughput scalability for large-scale phenotypic screening campaigns.
- Screening Solutions Large-scale phenotypic screening campaigns using siRNA, CRISPR, or small molecular compound libraries with high-content phenotypic readouts from microscopic imaging.
- Data Science Services AI-powered image and data analysis services, including tailored analysis tools developed by the KSILINK team for disease-specific applications.
- Myrtil Biotechnologies Spin-off Program Joint spin-off program with myriamed GmbH that conducts large-scale screening campaigns in dilated cardiomyopathies to identify new mechanisms of action, targets, and therapeutic molecules, generating value through equity and licensing arrangements.
Quantifiable outcome
- Successfully generated phenotypic profiles for patient-derived neurons that can classify disease vs healthy state with high accuracy
- +3 more outcomes
Companies that use KSILINK
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
KSILINK technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
KSILINK partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered major, core and minor.
- Oncodesign Precision MedicinemajorOncodesign Precision Medicine and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases, expanding Ksilink's CNS drug discovery capabilities
- University of LuxembourgcoreCollaboration using patient-derived cellular model for Parkinson's Disease based on SNCA triplication to identify and rescue phenotypes through morphological profiling
- University of ChietiminorCollaboration with researchers from University of Chieti in Italy on study of effects of Endocrine Disrupting Chemicals on human stem cell-derived neurons for Parkinson's disease research
- IMPACT ConsortiummajorEIC Pathfinder consortium on Cardiogenomics meets AI for arrhythmogenic cardiomyopathy diagnosis and treatment. Ksilink contributes phenotypic and functional profiling of cardiac muscle disorders as partner of 7-member consortium
- EnvironMENTAL ConsortiummajorEC-funded consortium coordinated by Charité Hospital focused on identifying molecular and neural mechanisms of environmentally-induced mental illness, with 20+ partners including Ksilink as SME
- Myrtil BiotechnologiesmajorJoint spin-off with myriamed GmbH based on AI-powered screenable disease model for dilated cardiomyopathies. Myrtil will conduct large-scale screening to identify new MOAs, targets and therapeutic molecules
- JUMP-Cell Painting Consortium (Broad Institute)coreKsilink joined consortium of 10 pharmaceutical companies, 6 technology companies, and 2 non-profit partners coordinated by Broad Institute to create largest cell-imaging dataset with 140,000+ perturbations
- myriamed GmbHcoreStrategic partnership with myriamed GmbH (spinoff of University Medical Center Göttingen) to discover new active pharmaceutical ingredients for treating heart muscle diseases, leading to Myrtil Biotechnologies spin-off
- Biological Adaptation and Ageing (B2A-IBPS) / Sorbonne UniversitycoreStrategic partnership with research unit of Institute of Biology Paris Seine (Sorbonne Université/CNRS/Inserm) to discover new APIs for heart muscle diseases
- I-StemcoreKsilink initiates drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with strategic partner I-Stem in Paris. Collaboration focuses on patient-based disease modeling and phenotypic screening.
- Luxembourg Centre for Systems Biomedicine (LCSB)coreKsilink teams up with LCSB of University of Luxembourg to develop drugs for Parkinson's disease using novel patient-based cell culture models with AI-powered automated testing of drug candidates
- SanofimajorSanofi and Ksilink entered research collaboration to accelerate discovery of next-generation therapies addressing unmet medical needs for Parkinson's disease patients, with Life & Brain contributing stem cell technologies
- Anagenesis BiotechnologiescoreCollaborative research agreement to apply stem-cell derived disease models of Duchenne Muscular Dystrophy to small molecule therapies discovery and development. Anagenesis achieved €3M seed funding subsequently
- University of Bonn / Life & Brain GmbHcoreAlliance to develop stem cell-based drug discovery approach for neurodegenerative diseases. Life & Brain provides stem cell technologies enabling disease modeling from patients.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
KSILINK competitors and assessment
Company assessmentEmerging players
- Owkin: Owkin applies AI to biomedical data including patient-derived multimodal datasets to accelerate drug discovery, partially overlapping with Ksilink's AI/biology intersection though more focused on data federation and clinical prediction.
- Cyclica: Cyclica is an AI-driven drug discovery company using proteome-wide and phenomic approaches to characterize drug candidates, comparable to Ksilink's AI-enabled, mechanism-agnostic profiling approach.
- CytoReason: CytoReason builds AI models of human cell biology and disease for pharma R&D, sharing Ksilink's emphasis on cellular-level AI to accelerate therapeutic discovery.
Direct peers
- Insitro: Insitro combines machine learning with patient-derived cellular disease models to discover novel therapeutics, closely mirroring Ksilink's patient-based, AI-enabled phenotypic drug discovery model.
- Cellarity: Cellarity develops medicines by targeting cellular behaviors rather than single molecular targets, using AI on cell-based phenotypic data—a near-direct analog to Ksilink's patient-based cellular profiling platform.
- Exscientia: Exscientia is an AI-native pharma combining computational design with phenotypic assays and patient-derived cells, operating in the same AI-enabled drug discovery category as Ksilink with multiple pharma partnerships.
- Recursion Pharmaceuticals: Recursion is a clinical-stage AI-driven drug discovery company using high-throughput phenotypic screening and machine learning on cellular imagery, directly overlapping with Ksilink's AI-boosted cellular profiling and target-agnostic discovery approach.
Broad incumbents
- Evotec: Evotec is a global contract research organization offering phenotypic screening, patient-derived disease models, and integrated drug discovery services to pharma, overlapping with Ksilink's discovery CRO activities but at much larger scale.
- Eurofins Discovery: Eurofins Discovery is a large CRO offering in vitro pharmacology, phenotypic screening, and integrated drug discovery services, competing with Ksilink for pharma service contracts across Europe and globally.
- Charles River Laboratories: Charles River is a major CRO providing phenotypic screening, cell-based assays, and drug discovery services across multiple therapeutic areas, making it a broad incumbent comparable to Ksilink's service offerings.
Market position
Strengths6 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
KSILINK social profiles
Digital presenceKSILINK financial estimates
Financial estimateRevenue estimate
Valuation estimate
KSILINK leadership team
Management profileNumber of profiles
Profiles8 records
KSILINK subsidiaries and ownership
Company hierarchySubsidiaries1 record
KSILINK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KSILINK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KSILINK
What does KSILINK do?
KSILINK designs and applies patient-derived and genome-edited cellular disease models for large-scale phenotypic drug discovery. It offers assay development, target identification, high-content phenotypic screening (using siRNA, CRISPR, and small molecule libraries), and AI-powered image and data analysis services to pharmaceutical, biotech, and academic partners. Its proprietary engine combines AI-boosted cellular profiling with patient-derived cellular systems to identify druggable targets and progress compounds toward clinical validation.
Is KSILINK a public or private company?
KSILINK is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was KSILINK founded?
KSILINK was founded in 2014. It employs 1 to 10 people.
Where is KSILINK based?
KSILINK is headquartered in Strasbourg, France, in the Europe region.
How does KSILINK make money?
Two revenue lines are on record. Drug Discovery Partnerships are the primary driver. The others are spin-off Companies.
Who are KSILINK's main competitors?
Emerging players on record are Owkin, Cyclica and CytoReason. Direct peers are Insitro, Cellarity, Exscientia and Recursion Pharmaceuticals. Broad incumbents are Evotec, Eurofins Discovery and Charles River Laboratories.
Does KSILINK have an API?
No public API is recorded for KSILINK.
What industry is KSILINK in?
KSILINK's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.